Currently in the Bahamas, patients with newly diagnosed breast and ovarian cancer undergo panel testing for which preliminary data suggest common BRCA1, BRCA2, and RAD51C variants.36,37 Because of differences in health systems across the region, participants in certain countries had low reports of ER, PR, and ERBB2, which may indicate limited molecular diagnostic testing. This evidence concerns the gene ERBB2 and ovarian carcinoma.